Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9861567 | 1.00 | CA4 (0.50) | CA4CA5ACA5B | |
| Hydrochloric Acid SCHEMBL8989477 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL2367899 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL11376427 | 1.00 | CA4 (0.50) | CA4CA5ACA5B | |
| Hydrochloric Acid SCHEMBL10678293 | 1.00 | CA4 (0.50) | CA4CA5ACA5B | |
| Hydrochloric Acid SCHEMBL9895093 | 1.00 | CA4 (0.50) | CA4CA5ACA5B | |
| Hydrochloric Acid SCHEMBL10762896 | 1.00 | CA4 (0.50) | CA4CA5ACA5B | |
| Hydrochloric Acid SCHEMBL9623636 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL1238246 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL11529429 | 1.00 | CA4 (0.50) | CA4CA5ACA5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736953-A2 | THERAPEUTIC AGENTS AND METHODS | Pop Test Oncology LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-3534910-B1 | RIFAMPICIN DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | POP TEST ONCOLOGY LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-11702443-B2 | Therapeutic agents and methods | POP TEST ONCOLOGY LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-11613620-B2 | Fibre reinforcement of reactive foams obtained by a moulding foam method | BASF SE (DE) | 2023-03-28 | — | — | US | disclosed |
| EP-4151682-A1 | FIBRE REINFORCEMENT OF REACTIVE FOAMS OBTAINED BY A DOUBLE BELT FOAMING OR A BLOCK FOAMING PROCESS | BASF SE (DE) | 2023-03-22 | — | — | EP | disclosed |
| EP-3464436-B1 | FIBRE REINFORCEMENT OF REACTIVE FOAMS OBTAINED BY A DOUBLE BELT FOAMING OR A BLOCK FOAMING METHOD | BASF SE (DE) | 2023-02-15 | — | — | EP | disclosed |
| US-20220298203-A1 | THERAPEUTIC AGENTS AND METHODS | POP TEST ONCOLOGY LLC | 2022-09-22 | — | — | US | disclosed |
| CN-109153807-B | Fiber-reinforced reactive foams obtained by the twin-strand or slabstock foaming process | 巴斯夫欧洲公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-109196031-B | Fiber reinforced reactive foams made by a molded foaming process | 巴斯夫欧洲公司 | 2022-01-28 | — | — | CN | disclosed |
| EP-3651973-B1 | METHOD FOR PRODUCING AT LEAST TWO-LAYER FOAM PANELS USING AT LEAST ONE THINNER DUROPLASTIC FOAMED PANEL WITH METAL COVER LAYERS BY MEANS OF BONDING | BASF SE (DE) | 2021-09-08 | — | — | EP | disclosed |
| EP-3651973-A2 | METHOD FOR MANUFACTURING FOAM PANELS HAVING AT LEAST TWO-LAYERS BY GLUEING, USING AT LEAST ONE THINNER DUROPLASTIC FOAM PANEL WITH METALLIC COVERING LAYERS | BASF SE (DE) | 2020-05-20 | — | — | EP | disclosed |
| EP-3534910-A2 | THERAPEUTIC AGENTS AND METHODS | Pop Test Oncology LLC (US) | 2019-09-11 | — | — | EP | disclosed |
| US-20190168426-A1 | FIBRE REINFORCEMENT OF REACTIVE FOAM MATERIAL OBTAINED BY A DOUBLE STRIP FOAM METHOD OR A BLOCK FOAM METHOD | BASE SE (DE) | 2019-06-06 | — | — | US | disclosed |
| EP-3464437-A1 | FIBRE REINFORCEMENT OF REACTIVE FOAMS OBTAINED BY A MOULDING FOAM METHOD | BASF SE (DE) | 2019-04-10 | — | — | EP | disclosed |
| EP-3464436-A1 | FIBRE REINFORCEMENT OF REACTIVE FOAM MATERIAL OBTAINED BY A DOUBLE STRIP FOAM METHOD OR A BLOCK FOAM METHOD | BASF SE (DE) | 2019-04-10 | — | — | EP | disclosed |
| WO-2018067520-A2 | THERAPEUTIC AGENTS AND METHODS: | POP TEST ONCOLOGY LLC (US) | 2018-04-12 | — | — | WO | disclosed |
| US-5837760-A | HALOGEN-FREE FLAMEPROOFING MIXTURE OF ORGANIC PHOSPHATE AND/OR PHOSPHONATE AND MELAMINE CYANURATE | ELASTOGRAN GMBH (DE) | 1998-11-17 | — | — | US | disclosed |
| US-4579649-A | CATALYST CONTAINING GROUP 6B AND GROUP 8 COMPONENTS AND A PHOSPHOROUS OXIDE | INTEVEP, S.A. (VE) | 1986-04-01 | — | — | US | disclosed |
| US-4520128-A | MIXED OXIDES OF GROUP VI OR VIII METALS ON ALUMINA SUPPORT | INTEVEP, S.A. (VE) | 1985-05-28 | — | — | US | disclosed |
| US-4210566-A | BLEND OF SOLVENTS, COLORANT, BINDER, AND ELECTROLYTE | AMERICAN CAN COMPANY (US) | 1980-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702443-B2 | Therapeutic agents and methods | NR1H4, NR3C1, NR3C2 | CA4 1926/4885CA5A 594/4885CA5B 770/4885 |
| US-20220298203-A1 | THERAPEUTIC AGENTS AND METHODS | NR1H4, NR3C1, NR3C2 | CA4 1926/4885CA5A 594/4885CA5B 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.